Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?

Abstract

Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are prescribed to slow the progression of kidney disease in patients with Alport syndrome. In a recent publication by Yamamura et al. the authors showed an association of ACEi or ARB treatment with delay in ESKD, even for those patients with severe, truncating mutations. Despite these encouraging findings, there remain a number of clinical questions about the use of ACEi and ARBs in Alport syndrome.

• Authors: Michelle N Rheault
• Journal: Kidney international (Kidney Int) Vol. 98 Issue 6 Pg. 1400-1402 (12 2020) ISSN: 1523-1755 [Electronic] United States
• PMID: 33276866 (Publication Type: Journal Article, Comment)
• Copyright: Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Chemical References

• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• Angiotensins
• Pharmaceutical Preparations

Topics

• Angiotensin Receptor Antagonists (adverse effects)
• Angiotensin-Converting Enzyme Inhibitors (adverse effects)
• Angiotensins
• Genetic Association Studies
• Humans
• Japan
• Male
• Nephritis, Hereditary (drug therapy, genetics)
• Pharmaceutical Preparations